What evidence gaps are holding back deep brain stimulation for psychiatric disorders?

Why have large trials failed to confirm the promise of DBS for psychiatric disorders?

The central controversy is a stark mismatch between open-label enthusiasm and controlled-trial disappointment. Open-label studies — where both patient and doctor know the treatment is on — often show striking improvements, with response rates in depression and obsessive-compulsive disorder (OCD) approaching 48% and 35%, respectively [3]. Yet when the same interventions are tested in randomized controlled trials (RCTs), the results have been underwhelming. Two multicenter trials of DBS for depression were terminated early because of a lack of efficacy [5], and a 2025 review notes that across psychiatric indications, the literature is 'constrained by inconsistent study designs, a paucity of randomized controlled trials, and heterogeneity in DBS targets and stimulation parameters' [3]. This pattern — strong signals in open-label work, weak signals in RCTs — is the single biggest evidence gap holding the field back.

The reasons for this gap are not fully understood, but a 2023 paper points to a key technical problem: DBS systems have many adjustable parameters, and clinicians receive little feedback on whether they have chosen the correct ones for an individual patient [6]. This 'dosing' problem means that even in a well-designed trial, the stimulation settings might be wrong for many participants, diluting any true treatment effect. Until researchers can reliably match stimulation parameters to individual brain states, RCTs may continue to struggle.

What don't we know about how DBS actually works in the brain?

A second major gap is the lack of a clear, agreed-upon mechanism of action for DBS in psychiatric disorders. While DBS is known to modulate neural circuits, the precise biological effects — how it alters neurotransmitter release, neural firing patterns, or long-term brain plasticity — remain poorly understood [1][7]. This is a critical problem because without knowing how the therapy works, it is nearly impossible to rationally design better targets, stimulation protocols, or patient selection criteria. A 2024 review of neuromodulation techniques emphasizes that 'ongoing research and clinical trials are vital for optimizing these technologies for personalized medicine, enhancing their efficacy and understanding of their mechanisms in various conditions' [1].

The mechanistic uncertainty is compounded by the fact that different psychiatric conditions may require different targets and stimulation parameters, yet there is no consensus on which target is best for which disorder. For example, a 2021 case study reported that low-voltage DBS of the substantia nigra pars reticulata (SNr) produced meaningful reductions in hallucinations in a patient with treatment-resistant schizophrenia, while a prior study used much higher voltage at a different site (nucleus accumbens) [2]. The authors note that 'it is not possible to extrapolate from this single case' and that 'the research is in its early days' [2]. Across the board, the field lacks the kind of dose-response and target-specificity data that would allow clinicians to make evidence-based choices.

How do we know if DBS is actually helping — and are we measuring the right things?

A third, often-overlooked gap is the poor quality and inconsistency of outcome measurement in psychiatric DBS studies. A 2025 systematic review found that out of 302 studies on DBS for psychiatric indications, only a tiny fraction measured sleep — a factor critically important to psychiatric health. Of those that did, methods varied wildly: some used subjective self-reports, others used wearable monitors, and only one used objective electroencephalography (EEG) [8]. The review concludes that 'current data is underpowered and the impact of DBS on sleep for psychiatric indications remains unknown' [8]. This is a microcosm of a larger problem: many studies rely on symptom scales that may not capture meaningful changes in real-world functioning or quality of life.

The measurement problem extends to safety and side effects. While DBS is generally considered safe, with a postsurgical complication rate of 1-3% in one schizophrenia study [2], a 2025 review of complications notes that controlled trials have yielded 'more modest results' than open-label studies, and that neuropsychiatric side effects — such as hypomania, apathy, and impulse control disorders — are underreported [9]. A 2022 study on rechargeable pulse generators found that 38.1% of psychiatric DBS patients experienced unintentional therapy interruptions, and the average charge burden was 286 minutes per week — significantly higher than in movement disorder patients [4]. These practical burdens are rarely captured in standard efficacy trials, meaning the true risk-benefit ratio for real-world patients remains unclear.

About These Sources

This answer is built on 9 peer-reviewed studies — published from 2016 to 2025, 4 from 2024 or later, 1 in Q1 journals — selected as the most relevant from 11 studies that passed quality screening, drawn from 58 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions